JP5528472B2 - クルクミン及びクルクミン誘導体のナノ乳化法 - Google Patents
クルクミン及びクルクミン誘導体のナノ乳化法 Download PDFInfo
- Publication number
- JP5528472B2 JP5528472B2 JP2011543881A JP2011543881A JP5528472B2 JP 5528472 B2 JP5528472 B2 JP 5528472B2 JP 2011543881 A JP2011543881 A JP 2011543881A JP 2011543881 A JP2011543881 A JP 2011543881A JP 5528472 B2 JP5528472 B2 JP 5528472B2
- Authority
- JP
- Japan
- Prior art keywords
- curcuminoid
- curcumin
- nonionic
- curcuminoids
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 title claims description 100
- 235000012754 curcumin Nutrition 0.000 title claims description 48
- 229940109262 curcumin Drugs 0.000 title claims description 48
- 239000004148 curcumin Substances 0.000 title claims description 48
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 title claims description 48
- 238000000034 method Methods 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 34
- 229930153442 Curcuminoid Natural products 0.000 claims description 30
- 239000002245 particle Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 239000006184 cosolvent Substances 0.000 claims description 16
- 239000002736 nonionic surfactant Substances 0.000 claims description 15
- 239000004094 surface-active agent Substances 0.000 claims description 12
- -1 polyphenol compound Chemical class 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- 235000013824 polyphenols Nutrition 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229940068968 polysorbate 80 Drugs 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 238000000527 sonication Methods 0.000 claims description 5
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 claims description 4
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 claims description 4
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 claims description 4
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008346 aqueous phase Substances 0.000 claims description 3
- JYTVKRNTTALBBZ-UHFFFAOYSA-N bis demethoxycurcumin Natural products C1=CC(O)=CC=C1C=CC(=O)CC(=O)C=CC1=CC=CC(O)=C1 JYTVKRNTTALBBZ-UHFFFAOYSA-N 0.000 claims description 3
- PREBVFJICNPEKM-YDWXAUTNSA-N bisdemethoxycurcumin Chemical compound C1=CC(O)=CC=C1\C=C\C(=O)CC(=O)\C=C\C1=CC=C(O)C=C1 PREBVFJICNPEKM-YDWXAUTNSA-N 0.000 claims description 3
- YXAKCQIIROBKOP-UHFFFAOYSA-N di-p-hydroxycinnamoylmethane Natural products C=1C=C(O)C=CC=1C=CC(=O)C=C(O)C=CC1=CC=C(O)C=C1 YXAKCQIIROBKOP-UHFFFAOYSA-N 0.000 claims description 3
- 238000004945 emulsification Methods 0.000 claims description 2
- 229940066429 octoxynol Drugs 0.000 claims description 2
- 229920002113 octoxynol Polymers 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229940068965 polysorbates Drugs 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 20
- 239000000243 solution Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000005063 solubilization Methods 0.000 description 8
- 230000007928 solubilization Effects 0.000 description 8
- 208000002177 Cataract Diseases 0.000 description 7
- 206010007759 Cataract nuclear Diseases 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 208000029552 nuclear cataract Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 230000003381 solubilizing effect Effects 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 150000002634 lipophilic molecules Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 230000001437 anti-cataract Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000007908 nanoemulsion Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 3
- 229960001471 sodium selenite Drugs 0.000 description 3
- 239000011781 sodium selenite Substances 0.000 description 3
- 235000015921 sodium selenite Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 235000003392 Curcuma domestica Nutrition 0.000 description 2
- 244000008991 Curcuma longa Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000011948 assay development Methods 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 235000003373 curcuma longa Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 235000013976 turmeric Nutrition 0.000 description 2
- 210000004127 vitreous body Anatomy 0.000 description 2
- JJATURCWNDKGTJ-KBXRYBNXSA-N (1e,6e)-1-[3-(dimethoxymethoxy)-4-hydroxyphenyl]-7-(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione Chemical compound C1=C(O)C(OC(OC)OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 JJATURCWNDKGTJ-KBXRYBNXSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- IZLBLUIBVMGMIY-ZZXKWVIFSA-N Cyclocurcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C=2OC(CC(=O)C=2)C=2C=C(OC)C(O)=CC=2)=C1 IZLBLUIBVMGMIY-ZZXKWVIFSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 238000010668 complexation reaction Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- IZLBLUIBVMGMIY-UHFFFAOYSA-N cyclocurcumin Natural products C1=C(O)C(OC)=CC(C=CC=2OC(CC(=O)C=2)C=2C=C(OC)C(O)=CC=2)=C1 IZLBLUIBVMGMIY-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000023611 glucuronidation Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 238000011045 prefiltration Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 229940082569 selenite Drugs 0.000 description 1
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000002047 solid lipid nanoparticle Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2112—Curcumin, turmeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/915—Therapeutic or pharmaceutical composition
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
従って、本発明は、非イオン性界面活性剤及び非イオン性共溶媒を特定濃度で用い、あわせて音波エネルギーを利用して、クルクミノイドなどの高親油性ポリフェノール化合物の水溶解度を向上させることを目的とする。
a)クルクミノイドと非イオン性界面活性剤ポリソルベート80との1:10比の混合物を撹拌するステップと、
b)クルクミノイド粒子を媒体中に十分に分散させるために撹拌を続けながら、非イオン性共溶媒であるポリエチレングリコールをクルクミンに関して1:10の比で添加するステップと、
c)前記混合物を、15〜30分間又はクルクミノイドが完全に可溶化するまで若しくは混合物中に目に見える粒子がなくなるまで音エネルギーを用いて超音波処理に付すステップと、
d)前記混合物を水性相中に分散させ、続いてよく撹拌して、クルクミノイドを水中に可溶化させるステップと、
を含む。
12gのクルクミン98%をガラスビーカー中に入れ、212gのポリソルベート80及び224gのポリエチレングリコール400を添加し、混合物を25KHzで30分間、完全に溶解するまで超音波処理する。
12gのビス−o−デメチルクルクミンをガラスビーカーに入れ、212gのポリソルベート80及び224gのポリエチレングリコール400を添加し、混合物を30分間25KHzで、完全に溶解するまで超音波処理する。
溶液Aの調製:
1.20gmのヒドロキシプロピルメチルセルロースを正確に秤量し、2Lの水(バッチサイズの10%)を含む容器にこれを添加し、約90℃に加熱し、一夜保持する。
2.前記溶液を翌日完全に分散するまで撹拌し、精製水で体積を6L(バッチサイズの30%)にし、これをよく撹拌して、均質な分散液を得る。
3.2μ前置フィルターを通して前記溶液を充填容器中に濾過する。この溶液を次いでオートクレーブ処理する。
1.14Lの精製水を新たに製造容器中に集める。4.67gのホウ砂を正確に秤量し、製造容器に添加する。完全に溶解するまで撹拌する;
2.4mlの塩化ベンザルコニウム溶液を正確に秤量し、製造容器に添加し、完全に溶解するまで撹拌する;
3.20gのエデト酸二ナトリウムを正確に秤量し、完全に溶解するまで撹拌しながら製造容器に添加する;そして
4.159gの塩化ナトリウムを正確に秤量し、完全に溶解するまで撹拌しながら製造容器に添加する。
1.12gのクルクミン98%を正確に秤量し、これをガラスビーカーに添加し;
2.212gのポリソルベート80を正確に測定し、好適なサイズのガラスビーカーに添加し;
3.224gのポリエチレングリコール400を正確に測定し、これをビーカーに添加し;そして
4.完全に溶解するまで、混合物を30分間超音波処理する。
1.「溶液C」を「溶液B」とともに添加し、よく撹拌し;
2.0.2μのフィルターを通して溶液を、「溶液A」を含むオートクレーブ処理された充填容器中に濾過し;そして
3.pHが5.8〜6.4であることをチェックする。
ナノ乳化配合物に関して実施した粒子サイズ分布の研究により、クルクミン分子が本発明の配合物中にナノサイズの粒子として存在することがさらに裏付けられる。この研究により、未配合形態で本来374nmであるクルクミン分子は、本発明者等の配合物によるクルクミンの輸送の向上及び有効性に望ましい独自の方法によって乳化されて8〜11nmのサイズの粒子になることが明らかになる。
前記配合物のバイオアベイラビリティをヒト肺癌線維芽細胞系のA549細胞系に関して研究した。これらは急速に成長する能力を有する接着細胞である。細胞を約90%のコンフルエンシーに達するまでDMEM培地中で培養し、その後細胞を12穴プレートに分割した。培養プレートが約90〜100%までコンフルエントになったら、実験に使用した。通常、105細胞/穴の播種密度では3日で約90%までコンフルエントな培養をもたらすことができる。
配合物の抗白内障効果に関するインビボ効能実験により、当該化合物は眼柵を通って透過し、網膜に到達することができ、ラットにおいて白内障形成を防止することが示される。
実験期間全体にわたってどの動物も毒性の臨床兆候及び死亡を示さなかった。I群(対照)動物の眼はすべて透明であることが判明した。II群において、亜セレン酸ナトリウムを注入された動物は、70%の眼が濃厚な混濁型白内障を発現し、20%の眼が強い核性白内障を発症し、10%の眼が核性白内障を発現し、一方、III群(治療)動物においては55%(11個の眼)で白内障は観察されず、10%(2個の眼)で強い核性白内障、10%(2個の眼)で核性白内障、及び25%(5個の眼)で水晶嚢下混濁が観察された。
Claims (9)
- 高親油性ポリフェノール化合物のナノ乳化法であって、
前記高親油性ポリフェノール化合物が天然又は合成的に誘導されるクルクミノイドであり、
非イオン性界面活性剤及び非イオン性共溶媒を用い、音波エネルギーを利用して、前記天然又は合成的に誘導されるクルクミノイドの水溶解度を向上させ、それによって得られた可溶化クルクミノイドの粒子サイズが8〜11nmの範囲に存在する、高親油性ポリフェノール化合物のナノ乳化法。 - 前記天然クルクミノイドが、クルクミン、ビスデメトキシクルクミン及び/又はデメトキシクルクミンから選択される、請求項1に記載の方法。
- 前記合成クルクミノイドが合成的に誘導されるビス−o−デメチルクルクミン及び/又は他のデメチル化クルクミノイドから選択される、請求項1に記載の方法。
- 前記界面活性剤がポリソルベート80及び20、ポロキサマー、オクトキシノール並びに任意の薬学的に許容される非イオン性界面活性剤から選択される、請求項1に記載の方法。
- 前記共溶媒がポリエチレングリコール(PEG)のクラスから選択される、請求項1に記載の方法。
- クルクミノイドと非イオン性界面活性剤との比が1:10の範囲である、請求項1に記載の方法。
- クルクミノイドと非イオン性共溶媒との比が1:10の範囲である、請求項1に記載の方法。
- 以下の
a.クルクミノイド及び非イオン性界面活性剤ポリソルベート80の1:10比の混合物を撹拌するステップと、
b.クルクミノイド粒子を媒体中に十分に分散させるために継続して撹拌しながら、非イオン性共溶媒であるポリエチレングリコールをクルクミノイドに関して1:10の比で添加するステップと、
c.前記混合物を15〜30分間、又はクルクミノイドが完全に溶解するまで、又は混合物中に粒子が見られなくなるまで超音波処理に付すステップと、
d.前記混合物を水性相中に分散させ、続いてよく撹拌してクルクミノイドを水中に可溶化させるステップと、
を含む、請求項1に記載のクルクミノイドの水溶解度を向上させるための方法。 - 前記クルクミノイドは、0.04%w/vから2.5%w/vの量で存在しうる、請求項1に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2828/CHE/2008 | 2008-11-17 | ||
IN2828CH2008 | 2008-11-17 | ||
PCT/IN2009/000651 WO2010070665A2 (en) | 2008-11-17 | 2009-11-17 | A process for nanoemulsification of curcumin and derivatives of curcumin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012508794A JP2012508794A (ja) | 2012-04-12 |
JP5528472B2 true JP5528472B2 (ja) | 2014-06-25 |
Family
ID=42269179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011543881A Expired - Fee Related JP5528472B2 (ja) | 2008-11-17 | 2009-11-17 | クルクミン及びクルクミン誘導体のナノ乳化法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8632815B2 (ja) |
EP (1) | EP2346492A4 (ja) |
JP (1) | JP5528472B2 (ja) |
CN (1) | CN102202652A (ja) |
AU (1) | AU2009329025A1 (ja) |
CA (1) | CA2743965A1 (ja) |
EA (1) | EA019446B1 (ja) |
WO (1) | WO2010070665A2 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8632815B2 (en) * | 2008-11-17 | 2014-01-21 | Laila Pharmaceutical Pvt., Ltd. | Process for nanoemulsification of curcumin and derivatives of curcumin |
EP2358378A4 (en) * | 2008-12-01 | 2012-08-08 | Laila Pharmaceuticals Pvt Ltd | TOPICAL FORMULATION FOR THE TREATMENT OF INFLAMMATORY DISEASE, SKIN AND SLAUGHTER DISEASES AND SIMILAR DISEASES |
EP2629763B1 (en) * | 2010-10-22 | 2017-12-06 | Vizuri Health Sciences LLC | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
AU2013264767A1 (en) * | 2012-05-22 | 2014-11-27 | Laila Pharmaceuticals Pvt. Ltd. | Novel highly bioavailable, water soluble and sustained release nanoformulations of hydrophobic plant derived compounds and extracts |
DE202012012130U1 (de) * | 2012-12-19 | 2014-03-21 | Aquanova Ag | Curcuminsolubilisat |
CN104224716B (zh) * | 2014-10-14 | 2016-08-31 | 哈尔滨工业大学 | 利用纳米乳化技术生产纳米微粒的方法 |
US10085951B2 (en) | 2014-12-11 | 2018-10-02 | Designs For Health, Inc. | Curcuminoid formulations and related methods of treatment |
CN105315143B (zh) * | 2015-10-16 | 2017-06-16 | 苏州大学 | 一种提高姜黄素水溶性及溶液光稳定性的方法 |
CA3038346C (en) | 2019-01-31 | 2022-03-29 | Nam Hai LAI | Process for producing a nano-cbd microemulsion system |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4263333A (en) * | 1979-09-12 | 1981-04-21 | General Foods Corporation | Curcumin-metal color complexes |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
KR100478001B1 (ko) | 2002-06-21 | 2005-03-23 | 박계정 | 2축 밸런스 머신 |
US7968115B2 (en) * | 2004-03-05 | 2011-06-28 | Board Of Regents, The University Of Texas System | Liposomal curcumin for treatment of cancer |
AU2005337331B2 (en) * | 2005-10-13 | 2011-10-20 | Laila Nutraceuticals | Process for producing enriched fractions of tetrahydroxycurcumin and tetrahydrotetrahydroxy-curcumin from the extracts of curcuma longa |
US9023395B2 (en) * | 2007-04-13 | 2015-05-05 | University Of North Texas Health Science Center At Fort Worth | Formulation of active agent loaded activated PLGA nanoparticles for targeted cancer nano-therapeutics |
ES2459876T3 (es) * | 2007-11-28 | 2014-05-12 | Commonwealth Scientific And Industrial Research Organisation | Nanoemulsiones |
WO2010010431A1 (en) * | 2008-07-24 | 2010-01-28 | National Institute Of Pharmaceutical Education And Research | Self-nano-emulsifying curcuminoids composition with enhanced bioavailability |
US8632815B2 (en) * | 2008-11-17 | 2014-01-21 | Laila Pharmaceutical Pvt., Ltd. | Process for nanoemulsification of curcumin and derivatives of curcumin |
WO2010070664A1 (en) * | 2008-11-17 | 2010-06-24 | Laila Pharmaceuticals Pvt. Ltd. | Curcuminoids and its metabolites for the application in ocular diseases |
-
2009
- 2009-11-17 US US13/129,424 patent/US8632815B2/en active Active
- 2009-11-17 EP EP09833075A patent/EP2346492A4/en not_active Withdrawn
- 2009-11-17 WO PCT/IN2009/000651 patent/WO2010070665A2/en active Application Filing
- 2009-11-17 AU AU2009329025A patent/AU2009329025A1/en not_active Abandoned
- 2009-11-17 EA EA201170688A patent/EA019446B1/ru not_active IP Right Cessation
- 2009-11-17 CA CA2743965A patent/CA2743965A1/en not_active Abandoned
- 2009-11-17 CN CN2009801423458A patent/CN102202652A/zh active Pending
- 2009-11-17 JP JP2011543881A patent/JP5528472B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2743965A1 (en) | 2010-06-24 |
EP2346492A4 (en) | 2012-12-05 |
EA201170688A1 (ru) | 2011-12-30 |
WO2010070665A3 (en) | 2010-10-28 |
EP2346492A2 (en) | 2011-07-27 |
WO2010070665A2 (en) | 2010-06-24 |
US8632815B2 (en) | 2014-01-21 |
AU2009329025A1 (en) | 2010-06-24 |
US20110229532A1 (en) | 2011-09-22 |
CN102202652A (zh) | 2011-09-28 |
AU2009329025A2 (en) | 2011-06-02 |
JP2012508794A (ja) | 2012-04-12 |
EA019446B1 (ru) | 2014-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5528472B2 (ja) | クルクミン及びクルクミン誘導体のナノ乳化法 | |
JP5775462B2 (ja) | 眼疾患に適用するためのクルクミノイドおよびその代謝物 | |
Yadav et al. | Atorvastatin-loaded solid lipid nanoparticles as eye drops: proposed treatment option for age-related macular degeneration (AMD) | |
Zhang et al. | Preparation and evaluation of naringenin-loaded sulfobutylether-β-cyclodextrin/chitosan nanoparticles for ocular drug delivery | |
Hassanzadeh et al. | Ferulic acid-loaded nanostructured lipid carriers: A promising nanoformulation against the ischemic neural injuries | |
US8759403B2 (en) | Curcuminoids and its metabolites for the application in allergic ocular/nasal conditions | |
KR101890503B1 (ko) | 안구 장애의 치료를 위한 막-부착성 자가-조립된 시스템 | |
Kaur et al. | Development of mirtazapine loaded solid lipid nanoparticles for topical delivery: Optimization, characterization and cytotoxicity evaluation | |
Wang et al. | Cyclodextrin-based ocular drug delivery systems: A comprehensive review | |
Zhao et al. | Reactive oxygen species‐responsive mitochondria‐targeted liposomal quercetin attenuates retinal ischemia–reperfusion injury via regulating SIRT1/FOXO3A and p38 MAPK signaling pathways | |
Li et al. | Micelles based on polyvinylpyrrolidone VA64: A potential nanoplatform for the ocular delivery of apocynin | |
Ponnaganti et al. | Preparation, characterization and evaluation of Chitosan Nanobubbles for the targeted delivery of Ibrutinib | |
Fang et al. | Vesicular phospholipid gels as topical ocular delivery system for treatment of anterior uveitis | |
Vincent et al. | A novel lipophenol quercetin derivative to prevent macular degeneration: Intravenous and oral formulations for preclinical pharmacological evaluation | |
CN112022807A (zh) | 用于治疗眼部疾病的用于递送水飞蓟宾和其他活性成分的纳米结构化制剂 | |
Wu et al. | Milk-derived exosome as delivery system for lutein encapsulation in alleviating dry eye disease | |
JPWO2016039422A1 (ja) | 点眼用懸濁製剤 | |
Youssef et al. | Formulation and in Vitro-Ex vivo evaluation of cannabidiol and Cannabidiol-Valine-Hemisuccinate loaded Lipid-Based nanoformulations for ocular applications | |
Shah et al. | Breaking barriers: Intranasal delivery of brexpiprazole-nanostructured lipid carriers targets the brain for effective schizophrenia treatment | |
Abd-Elaty et al. | Engineering a novel water-in-oil biocompatible microemulsion system for the ocular delivery of dexamethasone sodium phosphate in the treatment of acute uveitis | |
Srivastava et al. | QbD-driven thymoquinone laden nanoemulsion for glaucoma management: In vitro, ex vivo, and pre-clinical evaluation | |
US20230165804A1 (en) | Solid lipid nanoparticle for intracellular release of active substances and method for production the same | |
CN115737654A (zh) | 一种滴眼给药预防和/或治疗白内障的眼用制剂 | |
Nirbhavane et al. | Triamcinolone acetonide loaded-cationic nano-lipoidal formulation for uveitis | |
AU2011232745A1 (en) | Curcuminoids and its metabolites for the application in allergic nasal conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120904 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140219 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140317 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140415 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5528472 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |